Literature DB >> 7898722

Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology.

S D Silberstein1, W B Young.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7898722     DOI: 10.1212/wnl.45.3.577

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  10 in total

Review 1.  Pharmacologic treatment of migraine. Comparison of guidelines.

Authors:  A Schuurmans; C van Weel
Journal:  Can Fam Physician       Date:  2005-06       Impact factor: 3.275

2.  Refractory caffeine and ergot-induced cervico-cerebral vasospasm and stroke treated with combined medical and endovascular approach.

Authors:  Megan Miller; Avinash B Kumar; Charles R Callison
Journal:  Neuroradiology       Date:  2011-04-06       Impact factor: 2.804

Review 3.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Acute treatment of migraines.

Authors:  Arnaldo N Da Silva; Stewart J Tepper
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 5.749

Review 5.  Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action.

Authors:  Jonathan Jia Yuan Ong; Milena De Felice
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

6.  Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data.

Authors:  J N de Hoon; K A Poppe; H H Thijssen; H A Struijker-Boudier; L M Van Bortel
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

Review 7.  The clinician's approach to the management of headache.

Authors:  M Maizels
Journal:  West J Med       Date:  1998-03

8.  Medication Overuse Headache.

Authors:  William B. Young
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.598

9.  Acute migraine therapy: new drugs and new approaches.

Authors:  Teshamae S Monteith; Peter J Goadsby
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

Review 10.  Ergotamine and dihydroergotamine: a review.

Authors:  Marcelo E Bigal; Stewart J Tepper
Journal:  Curr Pain Headache Rep       Date:  2003-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.